Dyne Therapeutics, Inc. (DYN) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
DYN Revenue Growth
DYN Revenue Analysis (2014–2025)
As of May 8, 2026, Dyne Therapeutics, Inc. (DYN) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, DYN's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $1.47 billion in 2014.
When compared to Healthcare sector peers including SRPT (-2.2% YoY), CRSP (-88.9% YoY), and BMRN (+9.9% YoY). Compare DYN vs SRPT →
DYN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DYNCurrent | $0 | - | - | - | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% |
DYN Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-2,049,000 | - | $-468,184,000 | - |
| 2024 | $0 | - | $-2,243,000 | - | $-343,886,000 | - |
| 2023 | $0 | - | $-2,461,000 | - | $-242,162,000 | - |
| 2022 | $0 | - | $0 | - | $-170,962,000 | - |
| 2021 | $0 | - | $0 | - | $-150,025,000 | - |
| 2020 | $0 | - | $-700,000 | - | $-58,647,000 | - |
| 2019 | $0 | - | $-271,000 | - | $-13,826,000 | - |
| 2018 | $0 | -100.0% | $-24,000 | - | $-4,795,000 | - |
| 2017 | $506.0M | -63.0% | $-2,426,000,000 | -479.4% | $-412,000,000 | -81.4% |
| 2016 | $1.37B | +62.2% | $-915,000,000 | -67.0% | $-640,000,000 | -46.9% |
See DYN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DYN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DYN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDYN — Frequently Asked Questions
Quick answers to the most common questions about buying DYN stock.
Is DYN's revenue growth accelerating or slowing?
DYN TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is DYN's long-term revenue growth rate?
Dyne Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is DYN's revenue distributed by segment?
DYN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.